NCT05613478View on ClinicalTrials.gov

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2027

Conditions
Hepatocellular CarcinomaImmunotherapyPreoperative
Interventions
DRUG

Camrelizumab

Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery

DRUG

Apatinib Mesylate

Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery

PROCEDURE

Radical surgery

Radical surgery

PROCEDURE

Preoperative TACE treatment

TACE treatment before preoperative camrelizumab combined with apatinib mesylate

DRUG

Camrelizumab

Camrelizumab is administered at 200mg, q3w (at least 6 cycles) after radical surgery

DRUG

Apatinib Mesylate

Apatinib Mesylate is administered at 250mg, qd (at least 6 cycles) after radical surgery

Trial Locations (1)

210029

RECRUITING

Jiangsu Province Hospital, Nanjing

All Listed Sponsors
collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER